Voriconazole ( DrugBank: Voriconazole )


2 diseases
IDDisease name (Link within this page)Number of trials
60Aplastic anemia1
299Cystic fibrosis3

60. Aplastic anemia


Clinical trials : 235 Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-PRC-13003130
2013-04-012013-03-30Voriconazole tablet for primary prophylaxis of invasive fungal infection in patients with severe aplastic anemia: a prospective, randomized, controlled, multi-center trialThe efficacy and pharmacoeconimics of voriconazole tablet for primary prophylaxis of invasive fungal infection in patients with severe aplastic anemia Severe Aplastic Anemia (SAA)Trial group:Vfend? (Voriconazole tablet for oral) should be administered 6mg/kg at the first day for adults, and then 200mg, twice daily; 4-7mg/kg/d for children, divided into twice a day,with administration period no longer than 6 weeks.;control:without anti-fungal drug;Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCNULLCompleted365BothTrial group:50;control:50;China

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01576315
(ClinicalTrials.gov)
June 201429/3/2012ATCF (Azole Therapy in Cystic Fibrosis)Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus.Cystic Fibrosis;Aspergillus InfectionsDrug: Itraconazole/voriconazoleRennes University HospitalNULLCompleted12 YearsN/ABoth11Phase 2France;United Kingdom
2EUCTR2011-005799-41-GB
(EUCTR)
04/10/201221/08/2012Azole Therapy in Cystic Fibrosis (ATCF)Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and ofvoriconazole in patients with cystic fibrosis and presenting withpersistent positive sputums for Aspergillus - Azole Therapy in Cystic Fibrosis (ATCF) Cystic fibrosis
MedDRA version: 14.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.1;Level: HLT;Classification code 10003486;Term: Aspergillus infections;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: SPORANOX
Product Name: Sporanox 10 mg/ml Oral Solution
INN or Proposed INN: ITRACONAZOLE
Other descriptive name: SPORANOX
Trade Name: V-Fend
Product Name: VFEND 40 mg/ml powder for oral suspension
INN or Proposed INN: voriconazole
Other descriptive name: Vfend
CHU de Rennes (Rennes University Hospital Centre)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150United Kingdom
3EUCTR2006-006362-41-GB
(EUCTR)
05/04/200728/03/2007An open study on the pharmacokinetics and safety of oral voriconazole in adult patients with cystic fibrosis - Voriconazole in CFAn open study on the pharmacokinetics and safety of oral voriconazole in adult patients with cystic fibrosis - Voriconazole in CF Adult patients with cystic fibrosis
MedDRA version: 8.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Trade Name: Vfend
Product Name: Vfend
INN or Proposed INN: VORICONAZOLE
Leeds Teaching Hospital NHS TrustNULLNot Recruiting Female: yes
Male: yes
12 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom